MIRA Pharmaceuticals (MIRA) Stock Price, News & Analysis

Company Overview

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

Key Stats

• Today's Range: $1.53 to $1.59
• 50-Day Range: $1.13 to $2.02
• 52-Week Range: $0.73 to $2.70
• Volume: 135,698 shs
• Average Volume: 2.00 million shs
• Market Capitalization: $26.56 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.00
• Consensus Rating: Strong Buy

MIRA Pharmaceuticals Stock Analysis - MarketRank™

MIRA Pharmaceuticals scored higher than 41% of companies evaluated by MarketBeat, and ranked 1427th out of 1,836 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

MIRA Pharmaceuticals has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

MIRA Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for MIRA Pharmaceuticals are expected to grow in the coming year, from ($0.60) to ($0.54) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MIRA Pharmaceuticals is -3.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MIRA Pharmaceuticals is -3.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

MIRA Pharmaceuticals has a P/B Ratio of 12.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.30% of the float of MIRA Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

MIRA Pharmaceuticals has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MIRA Pharmaceuticals has recently increased by 414.36%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MIRA Pharmaceuticals does not currently pay a dividend.

Dividend Growth

MIRA Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.30% of the float of MIRA Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

MIRA Pharmaceuticals has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MIRA Pharmaceuticals has recently increased by 414.36%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: -0.25

News Sentiment

MIRA Pharmaceuticals has a news sentiment score of -0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for MIRA Pharmaceuticals this week, compared to 1 article on an average week.

Search Interest

9 people have searched for MIRA on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.

MarketBeat Follows

3 people have added MIRA Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, MIRA Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.65% of the stock of MIRA Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Only 35.16% of the stock of MIRA Pharmaceuticals is held by institutions.

MIRA Stock Analysis - Frequently Asked Questions

How have MIRA shares performed this year?

MIRA Pharmaceuticals' stock was trading at $1.14 at the beginning of 2025. Since then, MIRA shares have increased by 37.7% and is now trading at $1.57.

How were MIRA Pharmaceuticals' earnings last quarter?

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) announced its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.15) by $0.04.

When did MIRA Pharmaceuticals IPO?

MIRA Pharmaceuticals (MIRA) raised $9 million in an initial public offering on Thursday, August 3rd 2023. The company issued 1,275,000 shares at a price of $7.00 per share.

Who are MIRA Pharmaceuticals' major shareholders?

Top institutional investors of MIRA Pharmaceuticals include International Assets Investment Management LLC (0.21%). Insiders that own company stock include George Cappy, Erez Aminov and Brian Patrick Mcnulty.
View institutional ownership trends.

How do I buy shares of MIRA Pharmaceuticals?

Shares of MIRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of MIRA Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MIRA Pharmaceuticals investors own include Plug Power (PLUG), Workhorse Group (WKHS), FuelCell Energy (FCEL), Fortress Biotech (FBIO), Ovid Therapeutics (OVID), Alamos Gold (AGI) and GeoVax Labs (GOVX).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 8/05/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MIRA
• Previous Symbol: NASDAQ:MIRA
• CIK: 1904286
• Web: mirapharmaceuticals.com
• Phone: 737-289-0835
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Price Target and Rating

• Average Price Target for MIRA Pharmaceuticals: $14.00
• High Price Target: $17.00
• Low Price Target: $11.00
• Potential Upside/Downside: +791.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.51)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.85 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -341.08%
• Return on Assets: -272.93%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.86
• Quick Ratio: 12.86

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.13 per share
• Price / Book: 12.08

Miscellaneous

• Outstanding Shares: 16,920,000
• Free Float: 15,795,000
• Market Cap: $26.56 million
• Optionable: Not Optionable
• Beta: 1.77